Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression.
The objective of this study was to elucidate the biological significance of GnRH and antiprogestins and antiestrogen in leiomyoma and their interactions with ovarian steroid 'add-back' therapy. Leiomyoma and myometrial smooth muscle cells (LSMC and MSMC) were isolated and exposed to GnRH agonist (leuprolide acetate, LA), 17beta-estradiol (E2), medroxyprogesterone acetate (MPA), GnRH antagonist (Antide), estrogen antagonist, ICI182780 (Fulvestrant) and progesterone antagonists RU486 (Mifepristone) and ZK98299 (Onapristone) and combinations thereof. The rate of DNA synthesis, cell proliferation and transforming growth factor-beta (TGF-beta) expression were then determined. In both cell types, we found that in a dose-dependent manner, LA inhibited, whereas E2, MPA and the combination of E2 + MPA stimulated, the rate of DNA synthesis in these cells. Antide reversed the inhibitory effect of LA, while LA partly inhibited the stimulatory effect of the steroids. In addition, RU486, ICI182780 and ZK98299 at 0.1 micro mol/l or higher doses inhibited the rate of DNA synthesis and partly reversed the effects of E2 and/or MPA. We also found that LSMC expressed elevated levels of TGF-beta1 compared with MSMC. In both cell types, the effects of LA, E2, MPA, RU, ZK and ICI and combinations thereof on TGF-beta1 production were reflective of their effects on DNA synthesis. In line with this, TGF-beta1 was found to stimulate DNA synthesis and the E2-, TGF-beta1- or E2 + TGF-beta1-induced DNA synthesis was found to be inhibited by TGF-beta1 neutralizing antibodies and/or LA. In conclusion, the results provide further evidence that GnRH agonist- and RU486-induced leiomyoma regression is mediated in part through an interactive mechanism that results in altered cell growth and suppression of TGF-beta production.
Chegini
N
N
Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL 32610, USA. Chegini@obgyn.ufl.edu
Ma
C
C
Tang
X M
XM
Williams
R S
RS
D004958:Estradiol / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000031:analogs & derivatives*; D006067:Gonanes / Q000494:pharmacology; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D016729:Leuprolide / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D024510:Muscle Development / Q000187:drug effects / Q000502:physiology; D032389:Myocytes, Smooth Muscle / Q000378:metabolism; D009215:Myometrium / Q000187:drug effects / Q000254:growth & development; D009842:Oligopeptides / Q000494:pharmacology; D011372:Progestins / Q000037:antagonists & inhibitors*; D013256:Steroids / Q000494:pharmacology*; D015291:Transforming Growth Factors / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics
D020847:Estrogen Receptor Modulators; D006067:Gonanes; D009842:Oligopeptides; D011372:Progestins; D013256:Steroids; D015735:Mifepristone; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D015291:Transforming Growth Factors; C057022:iturelix; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide; C053238:onapristone